[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff0qsaIsGgweO0-C-kiPIOQq-AZIrVqBZHB9DWyFS_lQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":63,"rows":70},"Bavarian Nordic",[4],57,false,6,14,55442,5,0,[14,17,19,21,24,26,29,31],{"name":15,"count":16},"Smallpox",10,{"name":18,"count":11},"Chikungunya Virus",{"name":20,"count":11},"HIV Infections",{"name":22,"count":23},"Respiratory Syncytial Virus Infections",4,{"name":25,"count":23},"Cholera",{"name":27,"count":28},"COVID-19 Disease",2,{"name":30,"count":28},"Monkeypox (Mpox)",{"name":32,"count":28},"Breast Cancer",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06549530","Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections","2026-05-01","MVA-BN",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07199569","Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells","2026-11-30","Jynneos",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06899802","A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine","2027-02","MVA-BN-WEV",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06007183","Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination","2028-04","CHIKV VLP vaccine booster",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07003984","A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.","2028-12","CHIKV VLP vaccine",{"nctId":60,"briefTitle":61,"date":62,"intervention":58},"NCT07467707","An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","2030-05",[64,65,66,67,68,69],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[71,99,123,161,179,201,245,271,315,349,375,393,417,435,453,480,498,525,543,571,589,607,632,737,769,808,835,860,878,896,919,937,962,988,1011,1036,1054,1078,1104,1128,1146,1172,1190,1222,1247,1271,1298,1316,1334,1352,1370,1396,1421,1445,1471,1496],{"intervention":58,"totalTrials":28,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":95,"NA":97},{"trials":74,"activeCount":12},[],{"trials":76,"activeCount":12},[],{"trials":78,"activeCount":12},[],{"trials":80,"activeCount":28,"soonestReadout":57},[81,88],{"nctId":55,"briefTitle":56,"status":82,"phases":83,"primaryCompletion":57,"completion":57,"start":84,"enrollment":85,"conditions":86,"interventions":87},"RECRUITING",[67],"2025-06-05",720,[18],[58],{"nctId":60,"briefTitle":61,"status":89,"phases":90,"primaryCompletion":62,"completion":62,"start":91,"enrollment":92,"conditions":93,"interventions":94},"NOT_YET_RECRUITING",[67],"2026-05",6144,[18],[58],{"trials":96,"activeCount":12},[],{"trials":98,"activeCount":12},[],{"intervention":53,"totalTrials":100,"cells":101},1,{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":119,"NA":121},{"trials":103,"activeCount":12},[],{"trials":105,"activeCount":12},[],{"trials":107,"activeCount":12},[],{"trials":109,"activeCount":100,"soonestReadout":52},[110],{"nctId":50,"briefTitle":51,"status":111,"phases":112,"primaryCompletion":52,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"ACTIVE_NOT_RECRUITING",[67],"2028-08","2023-08-30",800,[117],"Chikungunya Virus Infection",[53],{"trials":120,"activeCount":12},[],{"trials":122,"activeCount":12},[],{"intervention":38,"totalTrials":124,"cells":125},3,{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":140,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":127,"activeCount":12},[],{"trials":129,"activeCount":12},[130],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT00189943","Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects","COMPLETED",[65],"2003-07","2001-04",90,[15],[38],{"trials":141,"activeCount":28,"soonestReadout":37},[142,149],{"nctId":35,"briefTitle":36,"status":111,"phases":143,"primaryCompletion":37,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},[66],"2026-05-07","2024-10-21",460,[30],[38],{"nctId":40,"briefTitle":41,"status":111,"phases":150,"primaryCompletion":42,"completion":42,"start":151,"enrollment":152,"conditions":153,"interventions":154},[66],"2025-10-27",970,[30],[43,38],{"trials":156,"activeCount":12},[],{"trials":158,"activeCount":12},[],{"trials":160,"activeCount":12},[],{"intervention":43,"totalTrials":100,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":164,"activeCount":12},[],{"trials":166,"activeCount":12},[],{"trials":168,"activeCount":100,"soonestReadout":42},[169],{"nctId":40,"briefTitle":41,"status":111,"phases":170,"primaryCompletion":42,"completion":42,"start":151,"enrollment":152,"conditions":171,"interventions":172},[66],[30],[43,38],{"trials":174,"activeCount":12},[],{"trials":176,"activeCount":12},[],{"trials":178,"activeCount":12},[],{"intervention":48,"totalTrials":100,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":195,"PHASE4":197,"NA":199},{"trials":182,"activeCount":12},[],{"trials":184,"activeCount":12},[],{"trials":186,"activeCount":100,"soonestReadout":47},[187],{"nctId":45,"briefTitle":46,"status":111,"phases":188,"primaryCompletion":47,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},[66],"2027-03","2025-03-10",411,[193],"Encephalitis",[48],{"trials":196,"activeCount":12},[],{"trials":198,"activeCount":12},[],{"trials":200,"activeCount":12},[],{"intervention":202,"totalTrials":124,"cells":203},"IMVAMUNE®",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":219,"PHASE4":231,"NA":243},{"trials":205,"activeCount":12},[],{"trials":207,"activeCount":12},[],{"trials":209,"activeCount":12},[210],{"nctId":211,"briefTitle":212,"status":133,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT02038881","Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection",[66],"2017-05-10","2014-04-28",87,[15],[202],{"trials":220,"activeCount":12},[221],{"nctId":222,"briefTitle":223,"status":133,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT01144637","A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",[67],"2013-11","2014-06","2013-02",4005,[15],[202],{"trials":232,"activeCount":12},[233],{"nctId":234,"briefTitle":235,"status":133,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":242},"NCT03472014","Special Access Program IMVAMUNE®",[68],"2014-11-14","2010-04-22",22,[241],"Vaccination",[202],{"trials":244,"activeCount":12},[],{"intervention":246,"totalTrials":100,"cells":247},"VAXCHORA",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":269},{"trials":249,"activeCount":12},[],{"trials":251,"activeCount":12},[],{"trials":253,"activeCount":12},[],{"trials":255,"activeCount":12},[],{"trials":257,"activeCount":12},[258],{"nctId":259,"briefTitle":260,"status":133,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT03220737","VAXCHORA Pediatric Study to Assess Safety and Immunogenicity",[68],"2019-09-10","2020-03-06","2017-07-21",550,[267],"Cholera (Disorder)",[246],{"trials":270,"activeCount":12},[],{"intervention":272,"totalTrials":124,"cells":273},"PXVX0200",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":288,"PHASE3":290,"PHASE4":311,"NA":313},{"trials":275,"activeCount":12},[],{"trials":277,"activeCount":12},[278],{"nctId":279,"briefTitle":280,"status":133,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT01585181","Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200",[65],"2012-08","2013-01","2012-04",66,[25],[272],{"trials":289,"activeCount":12},[],{"trials":291,"activeCount":12},[292,302],{"nctId":293,"briefTitle":294,"status":133,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT02100631","A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults",[67],"2015-02","2015-06","2014-05",398,[25],[272],{"nctId":303,"briefTitle":304,"status":133,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":310},"NCT01895855","Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera",[67],"2014-11","2013-09",197,[25],[272],{"trials":312,"activeCount":12},[],{"trials":314,"activeCount":12},[],{"intervention":316,"totalTrials":28,"cells":317},"CHIKV VLP\u002Fadjuvant",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":345,"NA":347},{"trials":319,"activeCount":12},[],{"trials":321,"activeCount":12},[],{"trials":323,"activeCount":12},[],{"trials":325,"activeCount":12},[326,335],{"nctId":327,"briefTitle":328,"status":133,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT05072080","A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)",[67],"2023-04-03","2021-09-29",3258,[18],[316],{"nctId":336,"briefTitle":337,"status":133,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT05349617","Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years",[67],"2023-06-19","2023-08-08","2022-05-12",413,[18],[316],{"trials":346,"activeCount":12},[],{"trials":348,"activeCount":12},[],{"intervention":350,"totalTrials":100,"cells":351},"ABNCoV2",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":371,"NA":373},{"trials":353,"activeCount":12},[],{"trials":355,"activeCount":12},[],{"trials":357,"activeCount":12},[],{"trials":359,"activeCount":12},[360],{"nctId":361,"briefTitle":362,"status":133,"phases":363,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":369},"NCT05329220","ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2",[67],"2023-03-15","2023-10-05","2022-08-30",4205,[27],[350,370],"Comirnaty",{"trials":372,"activeCount":12},[],{"trials":374,"activeCount":12},[],{"intervention":370,"totalTrials":100,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":389,"NA":391},{"trials":378,"activeCount":12},[],{"trials":380,"activeCount":12},[],{"trials":382,"activeCount":12},[],{"trials":384,"activeCount":12},[385],{"nctId":361,"briefTitle":362,"status":133,"phases":386,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":387,"interventions":388},[67],[27],[350,370],{"trials":390,"activeCount":12},[],{"trials":392,"activeCount":12},[],{"intervention":394,"totalTrials":100,"cells":395},"PXVX0200 Lot A",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":413,"NA":415},{"trials":397,"activeCount":12},[],{"trials":399,"activeCount":12},[],{"trials":401,"activeCount":12},[],{"trials":403,"activeCount":12},[404],{"nctId":405,"briefTitle":406,"status":133,"phases":407,"primaryCompletion":296,"completion":297,"start":298,"enrollment":408,"conditions":409,"interventions":410},"NCT02094586","A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults",[67],3146,[25],[394,411,412],"PXVX0200 Lot B","PXVX0200 Lot C",{"trials":414,"activeCount":12},[],{"trials":416,"activeCount":12},[],{"intervention":411,"totalTrials":100,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":431,"NA":433},{"trials":420,"activeCount":12},[],{"trials":422,"activeCount":12},[],{"trials":424,"activeCount":12},[],{"trials":426,"activeCount":12},[427],{"nctId":405,"briefTitle":406,"status":133,"phases":428,"primaryCompletion":296,"completion":297,"start":298,"enrollment":408,"conditions":429,"interventions":430},[67],[25],[394,411,412],{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":12},[],{"intervention":412,"totalTrials":100,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":449,"NA":451},{"trials":438,"activeCount":12},[],{"trials":440,"activeCount":12},[],{"trials":442,"activeCount":12},[],{"trials":444,"activeCount":12},[445],{"nctId":405,"briefTitle":406,"status":133,"phases":446,"primaryCompletion":296,"completion":297,"start":298,"enrollment":408,"conditions":447,"interventions":448},[67],[25],[394,411,412],{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[],{"intervention":454,"totalTrials":100,"cells":455},"MVA-BN-RSV vaccine",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":476,"NA":478},{"trials":457,"activeCount":12},[],{"trials":459,"activeCount":12},[],{"trials":461,"activeCount":12},[],{"trials":463,"activeCount":12},[464],{"nctId":465,"briefTitle":466,"status":467,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT05238025","MVA-BN-RSV Vaccine Trial","TERMINATED",[67],"2023-06-29","2023-09-01","2022-04-19",20419,[22],[454,475],"Tris Buffered Saline",{"trials":477,"activeCount":12},[],{"trials":479,"activeCount":12},[],{"intervention":475,"totalTrials":100,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":494,"NA":496},{"trials":483,"activeCount":12},[],{"trials":485,"activeCount":12},[],{"trials":487,"activeCount":12},[],{"trials":489,"activeCount":12},[490],{"nctId":465,"briefTitle":466,"status":467,"phases":491,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":492,"interventions":493},[67],[22],[454,475],{"trials":495,"activeCount":12},[],{"trials":497,"activeCount":12},[],{"intervention":499,"totalTrials":100,"cells":500},"MVA BN®",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":521,"NA":523},{"trials":502,"activeCount":12},[],{"trials":504,"activeCount":12},[],{"trials":506,"activeCount":12},[],{"trials":508,"activeCount":12},[509],{"nctId":510,"briefTitle":511,"status":133,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT01913353","A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®",[67],"2017-03","2017-08","2015-03",440,[518],"18-42 Year Old Healthy Vaccinia-naïve Subjects",[499,520],"ACAM2000®",{"trials":522,"activeCount":12},[],{"trials":524,"activeCount":12},[],{"intervention":520,"totalTrials":100,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":539,"NA":541},{"trials":528,"activeCount":12},[],{"trials":530,"activeCount":12},[],{"trials":532,"activeCount":12},[],{"trials":534,"activeCount":12},[535],{"nctId":510,"briefTitle":511,"status":133,"phases":536,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":537,"interventions":538},[67],[518],[499,520],{"trials":540,"activeCount":12},[],{"trials":542,"activeCount":12},[],{"intervention":544,"totalTrials":100,"cells":545},"PROSTVAC-V",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":567,"NA":569},{"trials":547,"activeCount":12},[],{"trials":549,"activeCount":12},[],{"trials":551,"activeCount":12},[],{"trials":553,"activeCount":12},[554],{"nctId":555,"briefTitle":556,"status":133,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":564},"NCT01322490","A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V\u002FF +\u002F- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer",[67],"2017-09-25","2017-12-15","2011-11-28",1297,[563],"Prostate Cancer Metastatic",[544,565,566],"PROSTVAC-F","GM-CSF",{"trials":568,"activeCount":12},[],{"trials":570,"activeCount":12},[],{"intervention":565,"totalTrials":100,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":585,"NA":587},{"trials":574,"activeCount":12},[],{"trials":576,"activeCount":12},[],{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":12},[581],{"nctId":555,"briefTitle":556,"status":133,"phases":582,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":583,"interventions":584},[67],[563],[544,565,566],{"trials":586,"activeCount":12},[],{"trials":588,"activeCount":12},[],{"intervention":566,"totalTrials":100,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":603,"NA":605},{"trials":592,"activeCount":12},[],{"trials":594,"activeCount":12},[],{"trials":596,"activeCount":12},[],{"trials":598,"activeCount":12},[599],{"nctId":555,"briefTitle":556,"status":133,"phases":600,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":601,"interventions":602},[67],[563],[544,565,566],{"trials":604,"activeCount":12},[],{"trials":606,"activeCount":12},[],{"intervention":608,"totalTrials":100,"cells":609},"FD MVA-BN",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":628,"NA":630},{"trials":611,"activeCount":12},[],{"trials":613,"activeCount":12},[],{"trials":615,"activeCount":12},[],{"trials":617,"activeCount":12},[618],{"nctId":619,"briefTitle":620,"status":133,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":627},"NCT03699124","Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial",[67],"2020-01-06","2020-06-22","2019-06-19",1129,[15],[608],{"trials":629,"activeCount":12},[],{"trials":631,"activeCount":12},[],{"intervention":633,"totalTrials":634,"cells":635},"IMVAMUNE",9,{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":651,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":637,"activeCount":12},[],{"trials":639,"activeCount":12},[640],{"nctId":641,"briefTitle":642,"status":133,"phases":643,"primaryCompletion":644,"start":645,"enrollment":646,"conditions":647,"interventions":650},"NCT00189917","Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders",[65],"2005-12","2004-04",60,[648,649],"Dermatitis, Atopic","Hay Fever",[633],{"trials":652,"activeCount":12},[653,664,674,683,694,705,713,722],{"nctId":654,"briefTitle":655,"status":133,"phases":656,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":662},"NCT00189930","An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients",[66],"2006-12","2005-04",77,[661],"HIV Infection",[663,633],"MVA-nef",{"nctId":665,"briefTitle":666,"status":133,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT00316589","Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients",[66],"2009-03","2009-10","2006-06",581,[20],[633],{"nctId":675,"briefTitle":676,"status":133,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":682},"NCT00857493","A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects",[66],"2010-08","2009-06",120,[15],[633,633],{"nctId":684,"briefTitle":685,"status":133,"phases":686,"primaryCompletion":687,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":693},"NCT00316602","A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis",[66],"2009-11","2010-04","2006-07",632,[692],"Atopic Dermatitis",[633],{"nctId":695,"briefTitle":696,"status":133,"phases":697,"primaryCompletion":698,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":703},"NCT00390078","Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection",[65,66],"2007-12","2009-01","2007-01",30,[20],[704,633],"MVA-mBN32",{"nctId":706,"briefTitle":707,"status":133,"phases":708,"start":709,"enrollment":710,"conditions":711,"interventions":712},"NCT00189904","Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients",[65,66],"2005-07",151,[20],[633],{"nctId":714,"briefTitle":715,"status":133,"phases":716,"primaryCompletion":717,"completion":679,"start":718,"enrollment":719,"conditions":720,"interventions":721},"NCT00686582","An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees",[66],"2008-12","2008-08",304,[15],[633,633],{"nctId":723,"briefTitle":724,"status":133,"phases":725,"primaryCompletion":726,"completion":644,"start":727,"enrollment":728,"conditions":729,"interventions":730},"NCT00189956","Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.",[66],"2003-11","2003-04",165,[15],[633],{"trials":732,"activeCount":12},[],{"trials":734,"activeCount":12},[],{"trials":736,"activeCount":12},[],{"intervention":738,"totalTrials":28,"cells":739},"MVA-BN-RSV",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":753,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":741,"activeCount":12},[],{"trials":743,"activeCount":12},[744],{"nctId":745,"briefTitle":746,"status":747,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":12,"conditions":751,"interventions":752},"NCT02864628","RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.","WITHDRAWN",[65],"2017-10-27","2016-09",[22],[738],{"trials":754,"activeCount":12},[755],{"nctId":756,"briefTitle":757,"status":133,"phases":758,"primaryCompletion":759,"completion":759,"start":750,"enrollment":760,"conditions":761,"interventions":762},"NCT02873286","RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults",[66],"2018-12",420,[22],[738],{"trials":764,"activeCount":12},[],{"trials":766,"activeCount":12},[],{"trials":768,"activeCount":12},[],{"intervention":770,"totalTrials":28,"cells":771},"CV301",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":788,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":773,"activeCount":12},[],{"trials":775,"activeCount":12},[776],{"nctId":777,"briefTitle":778,"status":133,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT02840994","A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer",[65],"2020-01","2016-12",24,[784],"Non-small Cell Lung Cancer (NSCLC)",[770,786,787],"Pembrolizumab","Nivolumab",{"trials":789,"activeCount":12},[790],{"nctId":791,"briefTitle":792,"status":133,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT03628716","CV301 Combined With PD-1\u002FL1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",[66],"2020-11-03","2021-02-02","2018-09-18",43,[799],"Bladder Cancer",[770,801],"Atezolizumab",{"trials":803,"activeCount":12},[],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":12},[],{"intervention":704,"totalTrials":28,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":823,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":811,"activeCount":12},[],{"trials":813,"activeCount":12},[814],{"nctId":815,"briefTitle":816,"status":133,"phases":817,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT00386633","Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection",[65],"2007-11","2006-10",36,[20],[704,704],{"trials":824,"activeCount":12},[825],{"nctId":695,"briefTitle":696,"status":133,"phases":826,"primaryCompletion":698,"completion":699,"start":700,"enrollment":701,"conditions":827,"interventions":828},[65,66],[20],[704,633],{"trials":830,"activeCount":12},[],{"trials":832,"activeCount":12},[],{"trials":834,"activeCount":12},[],{"intervention":836,"totalTrials":100,"cells":837},"LF formulation of IMVAMUNE®",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":839,"activeCount":12},[],{"trials":841,"activeCount":12},[],{"trials":843,"activeCount":12},[844],{"nctId":845,"briefTitle":846,"status":133,"phases":847,"primaryCompletion":848,"completion":226,"start":849,"enrollment":850,"conditions":851,"interventions":852},"NCT01668537","A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects",[66],"2014-01","2013-03",651,[15],[836,853],"FD formulation of IMVAMUNE®",{"trials":855,"activeCount":12},[],{"trials":857,"activeCount":12},[],{"trials":859,"activeCount":12},[],{"intervention":853,"totalTrials":100,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":863,"activeCount":12},[],{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":12},[868],{"nctId":845,"briefTitle":846,"status":133,"phases":869,"primaryCompletion":848,"completion":226,"start":849,"enrollment":850,"conditions":870,"interventions":871},[66],[15],[836,853],{"trials":873,"activeCount":12},[],{"trials":875,"activeCount":12},[],{"trials":877,"activeCount":12},[],{"intervention":801,"totalTrials":100,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":881,"activeCount":12},[],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[886],{"nctId":791,"briefTitle":792,"status":133,"phases":887,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":888,"interventions":889},[66],[799],[770,801],{"trials":891,"activeCount":12},[],{"trials":893,"activeCount":12},[],{"trials":895,"activeCount":12},[],{"intervention":897,"totalTrials":100,"cells":898},"Chikungunya",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":900,"activeCount":12},[],{"trials":902,"activeCount":12},[],{"trials":904,"activeCount":12},[905],{"nctId":906,"briefTitle":907,"status":133,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":646,"conditions":911,"interventions":912},"NCT03992872","Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)",[66],"2021-01-19","2019-11-20",[897],[897],{"trials":914,"activeCount":12},[],{"trials":916,"activeCount":12},[],{"trials":918,"activeCount":12},[],{"intervention":663,"totalTrials":100,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":12},[],{"trials":924,"activeCount":12},[],{"trials":926,"activeCount":12},[927],{"nctId":654,"briefTitle":655,"status":133,"phases":928,"completion":657,"start":658,"enrollment":659,"conditions":929,"interventions":930},[66],[661],[663,633],{"trials":932,"activeCount":12},[],{"trials":934,"activeCount":12},[],{"trials":936,"activeCount":12},[],{"intervention":938,"totalTrials":100,"cells":939},"MVA-BN®",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":941,"activeCount":12},[],{"trials":943,"activeCount":12},[],{"trials":945,"activeCount":12},[946],{"nctId":947,"briefTitle":948,"status":133,"phases":949,"primaryCompletion":950,"completion":951,"start":952,"enrollment":953,"conditions":954,"interventions":955},"NCT00316524","A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects",[66],"2007-02","2007-08","2006-04",745,[15],[938],{"trials":957,"activeCount":12},[],{"trials":959,"activeCount":12},[],{"trials":961,"activeCount":12},[],{"intervention":963,"totalTrials":100,"cells":964},"BN-Brachyury plus radiation",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":966,"activeCount":12},[],{"trials":968,"activeCount":12},[],{"trials":970,"activeCount":12},[971],{"nctId":972,"briefTitle":973,"status":133,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":981},"NCT03595228","BN Brachyury and Radiation in Chordoma",[66],"2021-12-10","2022-01-25","2018-10-31",29,[980],"Chordoma",[963],{"trials":983,"activeCount":12},[],{"trials":985,"activeCount":12},[],{"trials":987,"activeCount":12},[],{"intervention":989,"totalTrials":100,"cells":990},"PROSTVAC®-VF\u002FTRICOM™",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":992,"activeCount":12},[],{"trials":994,"activeCount":12},[],{"trials":996,"activeCount":12},[997],{"nctId":998,"briefTitle":999,"status":133,"phases":1000,"primaryCompletion":1001,"completion":699,"start":726,"enrollment":680,"conditions":1002,"interventions":1004},"NCT00078585","PROSTVAC®-VF\u002FTRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy",[66],"2006-01-04",[1003],"Prostate Cancer",[989],{"trials":1006,"activeCount":12},[],{"trials":1008,"activeCount":12},[],{"trials":1010,"activeCount":12},[],{"intervention":1012,"totalTrials":100,"cells":1013},"ABNCoV2 100ug",{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1015,"activeCount":12},[],{"trials":1017,"activeCount":12},[],{"trials":1019,"activeCount":12},[1020],{"nctId":1021,"briefTitle":1022,"status":133,"phases":1023,"primaryCompletion":1024,"completion":1025,"start":1026,"enrollment":308,"conditions":1027,"interventions":1028},"NCT05077267","ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects",[66],"2022-02-02","2023-10-31","2021-08-19",[27],[1012,1029],"ABNCoV2 50ug",{"trials":1031,"activeCount":12},[],{"trials":1033,"activeCount":12},[],{"trials":1035,"activeCount":12},[],{"intervention":1029,"totalTrials":100,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":12},[],{"trials":1041,"activeCount":12},[],{"trials":1043,"activeCount":12},[1044],{"nctId":1021,"briefTitle":1022,"status":133,"phases":1045,"primaryCompletion":1024,"completion":1025,"start":1026,"enrollment":308,"conditions":1046,"interventions":1047},[66],[27],[1012,1029],{"trials":1049,"activeCount":12},[],{"trials":1051,"activeCount":12},[],{"trials":1053,"activeCount":12},[],{"intervention":1055,"totalTrials":100,"cells":1056},"CHIKV VLP, adjuvanted",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1058,"activeCount":12},[],{"trials":1060,"activeCount":12},[],{"trials":1062,"activeCount":12},[1063],{"nctId":1064,"briefTitle":1065,"status":133,"phases":1066,"primaryCompletion":1067,"completion":1067,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1071},"NCT05065983","A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine",[66],"2022-05-05","2021-10-11",25,[18],[1055],{"trials":1073,"activeCount":12},[],{"trials":1075,"activeCount":12},[],{"trials":1077,"activeCount":12},[],{"intervention":1079,"totalTrials":100,"cells":1080},"MVA-mBN294B",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1082,"activeCount":12},[],{"trials":1084,"activeCount":12},[],{"trials":1086,"activeCount":12},[1087],{"nctId":1088,"briefTitle":1089,"status":133,"phases":1090,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT04752644","Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults",[66],"2021-06-17","2021-11-02","2021-02-22",73,[1096],"RSV Infection",[1079],{"trials":1099,"activeCount":12},[],{"trials":1101,"activeCount":12},[],{"trials":1103,"activeCount":12},[],{"intervention":1105,"totalTrials":100,"cells":1106},"MVA-mBN85B",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1108,"activeCount":12},[],{"trials":1110,"activeCount":12},[],{"trials":1112,"activeCount":12},[1113],{"nctId":1114,"briefTitle":1115,"status":133,"phases":1116,"primaryCompletion":1117,"completion":678,"start":679,"enrollment":137,"conditions":1118,"interventions":1120},"NCT00891007","Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years",[66],"2010-07",[1119],"Measles",[1105,1105,1121],"Rouvax",{"trials":1123,"activeCount":12},[],{"trials":1125,"activeCount":12},[],{"trials":1127,"activeCount":12},[],{"intervention":1121,"totalTrials":100,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":12},[],{"trials":1133,"activeCount":12},[],{"trials":1135,"activeCount":12},[1136],{"nctId":1114,"briefTitle":1115,"status":133,"phases":1137,"primaryCompletion":1117,"completion":678,"start":679,"enrollment":137,"conditions":1138,"interventions":1139},[66],[1119],[1105,1105,1121],{"trials":1141,"activeCount":12},[],{"trials":1143,"activeCount":12},[],{"trials":1145,"activeCount":12},[],{"intervention":1147,"totalTrials":100,"cells":1148},"CHIKV VLP\u002Funadjuvanted",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1150,"activeCount":12},[],{"trials":1152,"activeCount":12},[],{"trials":1154,"activeCount":12},[1155],{"nctId":1156,"briefTitle":1157,"status":133,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT03483961","Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults",[66],"2020-09-14","2020-09-21","2018-04-18",445,[117],[1147,1165],"CHIKV VLP\u002Fadjuvanted",{"trials":1167,"activeCount":12},[],{"trials":1169,"activeCount":12},[],{"trials":1171,"activeCount":12},[],{"intervention":1165,"totalTrials":100,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1175,"activeCount":12},[],{"trials":1177,"activeCount":12},[],{"trials":1179,"activeCount":12},[1180],{"nctId":1156,"briefTitle":1157,"status":133,"phases":1181,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1182,"interventions":1183},[66],[117],[1147,1165],{"trials":1185,"activeCount":12},[],{"trials":1187,"activeCount":12},[],{"trials":1189,"activeCount":12},[],{"intervention":1191,"totalTrials":28,"cells":1192},"MVA-BN-HER2",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1194,"activeCount":12},[],{"trials":1196,"activeCount":12},[1197,1205],{"nctId":1198,"briefTitle":1199,"status":133,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":634,"conditions":1203,"interventions":1204},"NCT00485277","A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer",[65],"2010-09","2007-06",[32],[1191],{"nctId":1206,"briefTitle":1207,"status":133,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT01152398","A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy",[65],"2012-09","2010-06",15,[32],[1191],{"trials":1215,"activeCount":12},[],{"trials":1217,"activeCount":12},[],{"trials":1219,"activeCount":12},[],{"trials":1221,"activeCount":12},[],{"intervention":1223,"totalTrials":100,"cells":1224},"MVA-BN-Brachyury\u002F FPV-Brachyury",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1239,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1226,"activeCount":12},[],{"trials":1228,"activeCount":12},[1229],{"nctId":1230,"briefTitle":1231,"status":133,"phases":1232,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1238},"NCT03349983","Safety and Tolerability Trial (MVA-BN-Brachyury\u002FFPV-Brachyury)",[65],"2020-06-13","2018-01-08",11,[1237],"Safety Issues",[1223],{"trials":1240,"activeCount":12},[],{"trials":1242,"activeCount":12},[],{"trials":1244,"activeCount":12},[],{"trials":1246,"activeCount":12},[],{"intervention":1248,"totalTrials":100,"cells":1249},"Elstree-BN",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1263,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1251,"activeCount":12},[],{"trials":1253,"activeCount":12},[1254],{"nctId":1255,"briefTitle":1256,"status":133,"phases":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1262},"NCT00189969","Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects",[65],"2006-02","2003-09",50,[15],[1248],{"trials":1264,"activeCount":12},[],{"trials":1266,"activeCount":12},[],{"trials":1268,"activeCount":12},[],{"trials":1270,"activeCount":12},[],{"intervention":1272,"totalTrials":100,"cells":1273},"MVA-BN-WEV Dose 1",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1275,"activeCount":12},[],{"trials":1277,"activeCount":12},[1278],{"nctId":1279,"briefTitle":1280,"status":133,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1287},"NCT04131595","Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects",[65],"2020-07-22","2019-10-07",45,[1286],"Equine Encephalitis",[1272,1288,1289],"MVA-BN-WEV Dose 2","MVA-BN-WEV Dose 3",{"trials":1291,"activeCount":12},[],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[],{"trials":1297,"activeCount":12},[],{"intervention":1288,"totalTrials":100,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":12},[],{"trials":1303,"activeCount":12},[1304],{"nctId":1279,"briefTitle":1280,"status":133,"phases":1305,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":1284,"conditions":1306,"interventions":1307},[65],[1286],[1272,1288,1289],{"trials":1309,"activeCount":12},[],{"trials":1311,"activeCount":12},[],{"trials":1313,"activeCount":12},[],{"trials":1315,"activeCount":12},[],{"intervention":1289,"totalTrials":100,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":12},[],{"trials":1321,"activeCount":12},[1322],{"nctId":1279,"briefTitle":1280,"status":133,"phases":1323,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":1284,"conditions":1324,"interventions":1325},[65],[1286],[1272,1288,1289],{"trials":1327,"activeCount":12},[],{"trials":1329,"activeCount":12},[],{"trials":1331,"activeCount":12},[],{"trials":1333,"activeCount":12},[],{"intervention":786,"totalTrials":100,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":12},[],{"trials":1339,"activeCount":12},[1340],{"nctId":777,"briefTitle":778,"status":133,"phases":1341,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1342,"interventions":1343},[65],[784],[770,786,787],{"trials":1345,"activeCount":12},[],{"trials":1347,"activeCount":12},[],{"trials":1349,"activeCount":12},[],{"trials":1351,"activeCount":12},[],{"intervention":787,"totalTrials":100,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":12},[],{"trials":1357,"activeCount":12},[1358],{"nctId":777,"briefTitle":778,"status":133,"phases":1359,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1360,"interventions":1361},[65],[784],[770,786,787],{"trials":1363,"activeCount":12},[],{"trials":1365,"activeCount":12},[],{"trials":1367,"activeCount":12},[],{"trials":1369,"activeCount":12},[],{"intervention":1371,"totalTrials":100,"cells":1372},"MVA-BN-Brachyury",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1374,"activeCount":12},[],{"trials":1376,"activeCount":12},[1377],{"nctId":1378,"briefTitle":1379,"status":133,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT04134312","A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",[65],"2021-01-12","2021-04-06","2020-01-08",13,[1386],"Solid Metastatic Tumor",[1371],{"trials":1389,"activeCount":12},[],{"trials":1391,"activeCount":12},[],{"trials":1393,"activeCount":12},[],{"trials":1395,"activeCount":12},[],{"intervention":1397,"totalTrials":100,"cells":1398},"MVA BN RSV",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1400,"activeCount":12},[],{"trials":1402,"activeCount":12},[1403],{"nctId":1404,"briefTitle":1405,"status":133,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1412},"NCT02419391","Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine",[65],"2015-12","2016-05","2015-08",63,[22],[1397],{"trials":1414,"activeCount":12},[],{"trials":1416,"activeCount":12},[],{"trials":1418,"activeCount":12},[],{"trials":1420,"activeCount":12},[],{"intervention":1422,"totalTrials":100,"cells":1423},"MVA-mBN120B",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1425,"activeCount":12},[],{"trials":1427,"activeCount":12},[1428],{"nctId":1429,"briefTitle":1430,"status":133,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":1211,"conditions":1435,"interventions":1436},"NCT00623259","Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects",[65],"2009-02","2009-04","2008-05",[20],[1422],{"trials":1438,"activeCount":12},[],{"trials":1440,"activeCount":12},[],{"trials":1442,"activeCount":12},[],{"trials":1444,"activeCount":12},[],{"intervention":1446,"totalTrials":100,"cells":1447},"TAEK-VAC-HerBy",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1449,"activeCount":12},[],{"trials":1451,"activeCount":12},[1452],{"nctId":1453,"briefTitle":1454,"status":133,"phases":1455,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1462},"NCT04246671","TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer",[65],"2024-02-17","2024-12-11","2020-08-10",37,[980,1461],"HER2-positive Breast Cancer",[1446],{"trials":1464,"activeCount":12},[],{"trials":1466,"activeCount":12},[],{"trials":1468,"activeCount":12},[],{"trials":1470,"activeCount":12},[],{"intervention":1472,"totalTrials":100,"cells":1473},"MVA-BN-PRO",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1475,"activeCount":12},[],{"trials":1477,"activeCount":12},[1478],{"nctId":1479,"briefTitle":1480,"status":133,"phases":1481,"primaryCompletion":1482,"completion":1483,"start":1484,"enrollment":782,"conditions":1485,"interventions":1487},"NCT00629057","A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer",[65],"2010-12","2011-09","2008-03",[1486],"Androgen-insensitive Prostate Cancer",[1472,1472,1472],{"trials":1489,"activeCount":12},[],{"trials":1491,"activeCount":12},[],{"trials":1493,"activeCount":12},[],{"trials":1495,"activeCount":12},[],{"intervention":1497,"totalTrials":100,"cells":1498},"Vivotif",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1500,"activeCount":12},[],{"trials":1502,"activeCount":12},[],{"trials":1504,"activeCount":12},[],{"trials":1506,"activeCount":12},[],{"trials":1508,"activeCount":12},[],{"trials":1510,"activeCount":12},[1511],{"nctId":1512,"briefTitle":1513,"status":133,"phases":1514,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT02391909","Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers",[],"2016-10-06","2017-02-21","2015-08-26",855,[1520],"Typhoid Fever",[1497]]